This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goel, A. Articles by Batra, S. K. Search for Related Content PubMed PubMed Citation Articles by Goel, A. Articles by Batra, S. K.

Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application¹

Departments of Biochemistry and Molecular Biology [A. G., S. K. B.], Radiation Oncology [J. B-K.], and Pathology and Microbiology [S. A., B. J. M. B., G. P., S. K. B.], College of Pharmacy [S. A.], Eppley Institute of Research in Cancer and Allied Diseases [S. K. B.], University of Nebraska Medical Center, Omaha, Nebraska 68198; and Coulter Pharmaceutical Incorporated, San Francisco, California 94080 [D. C.]

Failure of radiolabeled monoclonal antibodies (MAbs) in the treatment of solid tumors, for the most part, is a result of undesirable pharmacokinetics that lead to significant radiation exposure of normal tissues and an inadequate delivery of radiation doses to tumors. Using genetic engineering, antitumor MAbs can be optimized for desirable clinical applications. In the present study, we report the generation of a tetravalent single-chain Fv {[sc(Fv)₂]₂} of the murine MAb CC49 that recognizes the tumor-associated glycoprotein, TAG-72. [Sc(Fv)₂]₂ was expressed as a secreted soluble protein in Pichia pastoris under the regulation of alcohol oxidase 1 promoter. The in vitro binding properties of the tetravalent construct were analyzed by solid-phase RIA and surface plasmon resonance studies using BIAcore. The binding affinity constant (K_A) for the [sc(Fv)₂]₂ and CC49 IgG were similar, i.e., 1.02 x 10⁸ M^-1 and 1.14 x 10⁸ M^-1, respectively, and were 4-fold higher than its divalent scFv [sc(Fv)₂; 2.75 x 10⁷ M^-1]. At 6 h postadministration, the percentage of injected dose accumulated/g of LS-174T colon carcinoma xenografts was 21.3 ± 1.3, 9.8 ± 1.3, and 17.3 ± 1.1 for radioiodinated [sc(Fv)₂]₂, sc(Fv)₂, and IgG, respectively. Pharmacokinetic analysis of blood clearance studies showed the elimination half-life for [sc(Fv)₂]₂, sc(Fv)₂, and IgG as 170, 80, and 330 min, respectively. The gain in avidity resulting from multivalency along with an improved biological half-life makes the tetravalent construct an important reagent for cancer therapy and diagnosis in MAb-based radiopharmaceuticals.

This article has been cited by other articles:

				E. C. Peterson and S. M. Owens Designing Immunotherapies to Thwart Drug Abuse Mol. Interv., June 1, 2009; 9(3): 119 - 124. [Abstract] [Full Text] [PDF]

				E. C. Peterson, E. M. Laurenzana, W. T. Atchley, H. P. Hendrickson, and S. M. Owens Development and Preclinical Testing of a High-Affinity Single-Chain Antibody against (+)-Methamphetamine J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 124 - 133. [Abstract] [Full Text] [PDF]

				M. Jain, G. Venkatraman, and S. K. Batra Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their Modulation Clin. Cancer Res., March 1, 2007; 13(5): 1374 - 1382. [Abstract] [Full Text] [PDF]

				Y. Levites, K. Jansen, L. A. Smithson, R. Dakin, V. M. Holloway, P. Das, and T. E. Golde Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid beta, Amyloid beta40, and Amyloid beta42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice. J. Neurosci., November 15, 2006; 26(46): 11923 - 11928. [Abstract] [Full Text] [PDF]

				C.-Y. Xiong, A. Natarajan, X.-B. Shi, G. L. Denardo, and S. J. Denardo Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding Protein Eng. Des. Sel., August 1, 2006; 19(8): 359 - 367. [Abstract] [Full Text] [PDF]

				H. Karacay, P.-Y. Brard, R. M. Sharkey, C.-H. Chang, E. A. Rossi, W. J. McBride, D. R. Ragland, I. D. Horak, and D. M. Goldenberg Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft Clin. Cancer Res., November 1, 2005; 11(21): 7879 - 7885. [Abstract] [Full Text] [PDF]

				I. Burvenich, S. Schoonooghe, B. Cornelissen, P. Blanckaert, E. Coene, C. Cuvelier, N. Mertens, and G. Slegers In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131-Labeled Monoclonal Antibody 14C5 in a Non-Small Cell Lung Cancer and Colon Carcinoma Model Clin. Cancer Res., October 15, 2005; 11(20): 7288 - 7296. [Abstract] [Full Text] [PDF]

				M. Jain, S. C. Chauhan, A. P. Singh, G. Venkatraman, D. Colcher, and S. K. Batra Penetratin Improves Tumor Retention of Single-Chain Antibodies: A Novel Step toward Optimization of Radioimmunotherapy of Solid Tumors Cancer Res., September 1, 2005; 65(17): 7840 - 7846. [Abstract] [Full Text] [PDF]

				X. Cheng, Y. Zhang, N. Kotani, T. Watanabe, S. Lee, X. Wang, I. Kawashima, T. Tai, N. Taniguchi, and K. Honke Production of a Recombinant Single-Chain Variable-Fragment (scFv) Antibody against Sulfoglycolipid J. Biochem., March 1, 2005; 137(3): 415 - 421. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]

				F. Le Gall, U. Reusch, M. Little, and S. M. Kipriyanov Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody Protein Eng. Des. Sel., April 1, 2004; 17(4): 357 - 366. [Abstract] [Full Text] [PDF]

				M. Jain and S. K. Batra Genetically Engineered Antibody Fragments and PET Imaging: A New Era of Radioimmunodiagnosis J. Nucl. Med., December 1, 2003; 44(12): 1970 - 1972. [Full Text] [PDF]

				A. Goel, J. Baranowska-Kortylewicz, S. H. Hinrichs, J. Wisecarver, G. Pavlinkova, S. Augustine, D. Colcher, B. J.M. Booth, and S. K. Batra 99mTc-Labeled Divalent and Tetravalent CC49 Single-Chain Fv's: Novel Imaging Agents for Rapid In Vivo Localization of Human Colon Carcinoma J. Nucl. Med., October 1, 2001; 42(10): 1519 - 1527. [Abstract] [Full Text] [PDF]